Medtronic unit's valve replacement device gets approval in Europe

12/9/2010 | MedCityNews.com

Medtronic's CoreValve division has secured CE Mark approval for its a valve-replacement system that can treat severe aortic stenosis without requiring patients to undergo open-heart surgery. Medtronic paid $700 million to purchase CoreValve in 2009.

View Full Article in:

MedCityNews.com

Published in Brief:

SmartBrief Job Listings for Health Care